RAPPTA THERAPEUTICS
Rappta Therapeutics is a lead-optimization stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).
RAPPTA THERAPEUTICS
Industry:
Biopharma Biotechnology Life Science
Founded:
2006-01-01
Address:
Helsinki, Southern Finland, Finland
Country:
Finland
Website Url:
http://www.rappta-therapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
9 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Current Advisors List
Current Employees Featured
Founder
Investors List
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Rappta Therapeutics
Advent Life Sciences
Advent Life Sciences investment in Series A - Rappta Therapeutics
Novo Holdings
Novo Holdings investment in Series A - Rappta Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-15 | Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer |
Official Site Inspections
http://www.rappta-therapeutics.com
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Rappta Therapeutics"
Our Team - Rappta Therapeutics
Before joining Rappta Therapeutics, Sara was Head of Innovation at HIS, the commercialization arm of the University of Helsinki, and IPR Manager at the Technical Research Centre of …See details»
About Us | Rappta Therapeutics
Rappta Therapeutics is a late pre-clincal stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecular glues that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary …See details»
Investments · rappta-therapeutics - Novo Holdings
Rappta Therapeutics is working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). ... a Danish networking organization …See details»
Rappta Therapeutics - Crunchbase Company Profile
Organization. Rappta Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Rappta Therapeutics is a lead-optimization stage biopharmaceutical company. …See details»
Rappta Therapeutics enters into a global license agreement with ...
2 days ago About Rappta Therapeutics. Rappta Therapeutics, a private biotech with operations in Finland and the US, is developing first-in-class anti-cancer drugs activating protein …See details»
Rappta Therapeutics Oy - FIB
Jan 27, 2021 Rappta Therapeutics, a private biotech with operations in Finland and the US, is developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A). It has …See details»
SpringWorks to Develop Rappta’s First-in-Class Cancer Drug
2 days ago Rappta Therapeutics, a private biotech focused on developing anti-cancer drugs activating protein phosphatase 2A (PP2A), has announced an exclusive global license …See details»
Rappta Therapeutics - Products, Competitors, Financials, …
Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer. Sep 15, 2021 - Experienced industry leader with successful track-record in oncology to lead Rappta through …See details»
Evotec and Rappta Therapeutics enter discovery and development ...
Nov 24, 2020 Mikko Mannerkoski, the CEO of Rappta Therapeutics, added: “We are excited to be working on building a new platform and a novel class of pharmaceuticals to treat cancer. …See details»
Rappta Therapeutics enters into a global license agreement with ...
3 days ago Goutham Narla, Chief Scientific Officer of Rappta Therapeutics and Professor of Internal Medicine and Human Genetics at the University of Michigan, said: “Our team at …See details»
Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive …
Sep 15, 2021 [email protected]. Optimum Strategic Communications Mary Clark, Manel Mateus, Vici Rabbetts +44 (0) 20 3922 1906 [email protected]. …See details»
Rappta Therapeutics enters into a global license a…
2 days ago Goutham Narla, Chief Scientific Officer of Rappta Therapeutics and Professor of Internal Medicine and Human Genetics at the University of Michigan, said: “Our team at …See details»
Rappta Therapeutics Company Profile - Office Locations ... - Craft
Rappta Therapeutics has 5 employees at their 1 location and $10.63 m in total funding,. See insights on Rappta Therapeutics including office locations, competitors, revenue, financials, …See details»
Rappta Therapeutics enters global license agreement with …
1 day ago Rappta Therapeutics, a private biotech with operations in Finland and the US, is developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A). …See details»
Rappta Therapeutics Company Profile 2025: Valuation, Funding ...
Rappta Therapeutics General Information Description. Operator of a pharmaceutical company intended to develop a key tumor suppressor and a critical enzyme. The company's scientists …See details»
Targeting PP2A to tackle cancers: Rappta closes €9m Series A round
Oct 21, 2020 Oncology-focused Rappta Therapeutics has raised €9m in a Series A funding round co-led by the Novartis Venture Fund (NVF) and Novo Holdings through its early-stage …See details»
News - Rappta Therapeutics
Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs. Unique phosphatase technology platform offers a new paradigm in oncology. EUR 9M …See details»
Rappta Therapeutics Inc. - VentureRadar
Rappta Therapeutics Finland Privately Held Rappta Therapeutics is a lead-optimization stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecules …See details»
Rappta Therapeutics partners with SpringWorks Therapeutics
2 days ago Helsinki-based Rappta Therapeutics has entered into a global license agreement with SpringWorks Therapeutics for the development of RPT04402, a first-in-class molecular …See details»
Rappta Therapeutics Raises Series A Financing for the …
Oct 13, 2020 Rappta Therapeutics (“Rappta”), focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A), announces today the closing of a EUR 9 …See details»